TRCT
ARMP icon

Tower Research Capital (TRC)’s Armata Pharmaceuticals ARMP Stock Holding History

Tower Research Capital (TRC)’s Portfolio ARMP Stock Details ARMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.2K Buy
2,034
+1,757
+634% +$16.1K ﹤0.01% 3870
2026
Q1 		$2.84K Sell
277
-1,327
-83% -$11.2K ﹤0.01% 4410
2025
Q4 		$10.1K Buy
1,604
+1,249
+352% +$6.84K ﹤0.01% 3841
2025
Q3 		$1.06K Sell
355
-1,350
-79% -$3.49K ﹤0.01% 4887
2025
Q2 		$3.24K Sell
1,705
-1,766
-51% -$2.86K ﹤0.01% 4532
2025
Q1 		$5.07K Buy
3,471
+159
+5% +$317 ﹤0.01% 4165
2024
Q4 		$6.13K Buy
3,312
+1,307
+65% +$2.94K ﹤0.01% 4200
2024
Q3 		$4.75K Sell
2,005
-3,059
-60% -$7.82K ﹤0.01% 4433
2024
Q2 		$13.9K Buy
5,064
+3,367
+198% +$9.61K ﹤0.01% 3969
2024
Q1 		$7.09K Sell
1,697
-1,670
-50% -$6.05K ﹤0.01% 4261
2023
Q4 		$10.9K Sell
3,367
-2,210
-40% -$5.22K ﹤0.01% 4187
2023
Q3 		$16.7K Buy
5,577
+1,343
+32% +$3.6K ﹤0.01% 3535
2023
Q2 		$4.83K Buy
4,234
+1,091
+35% +$1.59K ﹤0.01% 4898
2023
Q1 		$5K Sell
3,143
-4,032
-56% -$9.37K ﹤0.01% 4927
2022
Q4 		$9K Buy
7,175
+6,271
+694% +$16.3K ﹤0.01% 4160
2022
Q3 		$4K Sell
904
-209
-19% -$841 ﹤0.01% 5222
2022
Q2 		$4K Buy
+1,113
New +$4.83K ﹤0.01% 5165
2021
Q4 		– Sell
-866
Closed -$3K – 6116
2021
Q3 		$3K Buy
866
+808
+1,393% +$3.08K ﹤0.01% 5074
2021
Q2 		$0 Sell
58
-928
-94% -$3.9K ﹤0.01% 5450
2021
Q1 		$5K Sell
986
-3,688
-79% -$18.1K ﹤0.01% 4645
2020
Q4 		$14K Buy
4,674
+2,404
+106% +$7.64K ﹤0.01% 4085
2020
Q3 		$7K Buy
2,270
+173
+8% +$609 ﹤0.01% 4221
2020
Q2 		$8K Buy
+2,097
New +$7.27K ﹤0.01% 4093
2016
Q1 		– Sell
-3
Closed -$2K – 4078
2015
Q4 		$2K Buy
3
+1
+50% +$766 ﹤0.01% 3680
2015
Q3 		$1K Buy
+2
New +$1.83K ﹤0.01% 3560

Other funds holding ARMP

MAM
Madison Asset Management Madison, Wisconsin $8.39B AUM 16.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
DIG
Dauntless Investment Group Etna, New Hampshire $127M AUM 42.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Edgewood Management
Edgewood Management Greenwich, Connecticut $9.69B AUM 6.52% 1-Year Est. Return

Tower Research Capital (TRC)'s ARMP Position: Q2 2026 in Review

Tower Research Capital (TRC) increased its Armata Pharmaceuticals (ARMP) stake by 634% in Q2 2026, buying an estimated $16.1K and bringing the position to 2,034 shares worth $13.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3870.

Tower Research Capital (TRC) first reported a position in ARMP in Q3 2015 and has held it in 25 quarters since. The position peaked at $16.7K in Q3 2023. 53 funds tracked by Wall St. Rank hold ARMP as of Q2 2026.

  • Tower Research Capital (TRC) held 2,034 shares of Armata Pharmaceuticals worth $13.2K as of Q2 2026.
  • Tower Research Capital (TRC) bought 1,757 Armata Pharmaceuticals shares in Q2 2026, an estimated $16.1K.
  • Armata Pharmaceuticals made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #3870 holding.
  • Tower Research Capital (TRC) first reported a position in Armata Pharmaceuticals in Q3 2015 and has held it in 25 quarters since.
  • Tower Research Capital (TRC)'s Armata Pharmaceuticals position peaked at $16.7K in Q3 2023.
  • 53 funds tracked by Wall St. Rank held Armata Pharmaceuticals as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.